Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Table 2. Costs used for the analysis of cost-effectiveness ... SCT, Stem cell transplantation; TKIs, Tyrosine kinase inhibitors; US, United States; WHO, World Health Organization; WTP, ...

This article will describe the development of erlotinib, an EGFR tyrosine kinase inhibitor (EGFR-TKI), focusing on the clinical data reported in the treatment of NSCLC. Clorinda Schettino ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...